AR117963A2 - Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina - Google Patents

Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Info

Publication number
AR117963A2
AR117963A2 ARP200100066A ARP200100066A AR117963A2 AR 117963 A2 AR117963 A2 AR 117963A2 AR P200100066 A ARP200100066 A AR P200100066A AR P200100066 A ARP200100066 A AR P200100066A AR 117963 A2 AR117963 A2 AR 117963A2
Authority
AR
Argentina
Prior art keywords
formula
chiral auxiliary
alkyl
nucleophile
preparation
Prior art date
Application number
ARP200100066A
Other languages
English (en)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117963(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR117963A2 publication Critical patent/AR117963A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (1) o una sal, hidrato, solvato o polimorfo farmacéuticamente aceptable de éste, en donde: R¹ es -CH₃; y cada uno de R², R³, R⁴, R⁵ y R⁶ es en cada aparición independientemente hidrógeno, halo, alquilC₁₋₆, alcoxiC₁₋₆, -CF₃, -CN o -NO₂, caracterizado porque comprende: (a) la condensación de un auxiliar quiral con un aldehído que tiene la fórmula (2); (b) la adición de un nucleófilo al producto condensado; y (c) la desprotección del producto de adición, en donde el nucleófilo es el anión litio de dimetilsulfona. Reivindicación 10: Un proceso para la preparación de un compuesto de fórmula (1) o una sal, hidrato, solvato o polimorfo farmacéuticamente aceptable de éste, en donde: R¹ es alquilC₁₋₆; y cada uno de R², R³, R⁴, R⁵ y R⁶ es en cada aparición independientemente hidrógeno, halo, alquilC₁₋₆, alcoxiC₁₋₆, CF₃, -CN o -NO₂, caracterizado porque comprende transformaciones sintéticas seleccionadas del grupo que consiste en: 1) la adición de un auxiliar quiral a una estirilsulfona, en donde el auxiliar quiral es (S)-a-metilbencilamina y la estirilsulfona es de fórmula (3); 2) la transaminación enzimática, en donde el material de partida es de fórmula (4); 3) la reducción diastereoselectiva de borohidruro de un aducto de Ellman, en donde el aducto de Ellman es de fórmula (5), R¹’, R²’, R³’, R⁴’ y R⁵’ son en cada aparición independientemente hidrógeno o alquilC₁₋₆, y el agente de reducción de borohidruro es borohidruro de sodio; 4) la adición estereoselectiva de anión de arilo a aldimina con auxiliar quiral, en donde el anión de arilo es de fórmula (6), la aldimina es de fórmula (7), y el auxiliar quiral es ter-butilsulfinilimina; 5) la epoxidación asimétrica y la apertura de anillo con un nucleófilo de azufre, en donde el material de partida de la epoxidación asimétrica es de fórmula (8), el material de partida de la apertura de anillo es de fórmula (9), y el nucleófilo de azufre es tiometóxido; y sus combinaciones.
ARP200100066A 2012-02-21 2020-01-10 Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina AR117963A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21

Publications (1)

Publication Number Publication Date
AR117963A2 true AR117963A2 (es) 2021-09-08

Family

ID=47755073

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100512A AR090100A1 (es) 2012-02-21 2013-02-19 Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
ARP200100066A AR117963A2 (es) 2012-02-21 2020-01-10 Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130100512A AR090100A1 (es) 2012-02-21 2013-02-19 Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Country Status (36)

Country Link
US (3) US9187417B2 (es)
EP (4) EP3702347B1 (es)
JP (1) JP2015509496A (es)
KR (1) KR101993248B1 (es)
CN (3) CN112812044B (es)
AR (2) AR090100A1 (es)
AU (1) AU2013203283B2 (es)
BR (3) BR122021020040B1 (es)
CA (1) CA2864517A1 (es)
CO (1) CO7061071A2 (es)
CR (1) CR20140395A (es)
CY (2) CY1121833T1 (es)
DK (2) DK3312156T3 (es)
ES (4) ES2675168T3 (es)
HR (2) HRP20191249T1 (es)
HU (2) HUE044192T2 (es)
IL (3) IL234135A (es)
IN (1) IN2014DN06740A (es)
LT (2) LT3378850T (es)
MX (2) MX344190B (es)
MY (1) MY168296A (es)
NI (1) NI201400093A (es)
NZ (1) NZ628028A (es)
PH (1) PH12014501865B1 (es)
PL (2) PL3312156T3 (es)
PT (2) PT3378850T (es)
RS (2) RS59071B1 (es)
RU (1) RU2632875C2 (es)
SG (1) SG11201405035XA (es)
SI (2) SI3312156T1 (es)
SM (2) SMT202000107T1 (es)
TR (1) TR201910430T4 (es)
TW (1) TW201336815A (es)
UA (1) UA116773C2 (es)
WO (1) WO2013126360A2 (es)
ZA (1) ZA201405892B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090100A1 (es) 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
EP3539539B1 (en) 2013-06-17 2025-11-05 Amgen (Europe) GmbH Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (es) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
EP3307711A1 (en) * 2015-06-09 2018-04-18 Dr. Reddy's Laboratories Ltd. Process for preparation of apremilast and its intermediates
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
EP3356327A1 (en) 2015-09-29 2018-08-08 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10399942B2 (en) 2015-11-19 2019-09-03 Alembic Pharmaceuticals Limited Process and novel polymorphic form of Apremilast
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
JP6684968B2 (ja) 2016-11-10 2020-04-22 エス・エム・エス・グループ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 連続鋳造圧延設備内において、金属的なストリップを製造するための方法
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
SI3606908T1 (sl) 2017-04-04 2020-10-30 Quimica Sintetica, S.A. Delitev racemičnih beta-aminosulfonskih spojin
EP3606907B1 (en) 2017-04-04 2021-01-20 Quimica Sintetica, S.A. Racemic beta-aminosulfone compounds
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
WO2023116707A1 (zh) 2021-12-21 2023-06-29 赣州和美药业有限公司 噻吩衍生物的制备
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 （s）-1-(3-乙氧基-4-甲氧基苯基)-2-（甲磺酰基）乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
PL329070A1 (en) 1996-03-22 1999-03-15 Du Pont Pharm Co Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
BR0317885A (pt) 2002-12-30 2005-12-06 Celgene Corp Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
EA018462B1 (ru) * 2008-01-25 2013-08-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК МОДУЛЯТОРЫ СИНТЕЗА TNF-α И КАК ИНГИБИТОРЫ PDE4
EP2334639B1 (en) * 2008-09-10 2013-01-23 Celgene Corporation Processes for the preparation of aminosulfone compounds
ES2469849T3 (es) 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
ES2451350T3 (es) 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds

Also Published As

Publication number Publication date
US9187417B2 (en) 2015-11-17
EP2817288B1 (en) 2018-05-30
CY1121833T1 (el) 2020-10-14
PL3312156T3 (pl) 2019-10-31
EP3378850A1 (en) 2018-09-26
HK1205501A1 (en) 2015-12-18
US9586897B2 (en) 2017-03-07
CN104245668B (zh) 2017-05-17
EP3702347A1 (en) 2020-09-02
WO2013126360A3 (en) 2013-10-31
US20130217918A1 (en) 2013-08-22
CN107033042A (zh) 2017-08-11
CN104245668A (zh) 2014-12-24
IL234135A (en) 2017-06-29
EP3312156A1 (en) 2018-04-25
BR112014020444A2 (pt) 2020-10-27
EP3312156B1 (en) 2019-06-05
CN112812044A (zh) 2021-05-18
ZA201405892B (en) 2015-11-25
BR122021020040B1 (pt) 2022-05-31
CY1122799T1 (el) 2021-05-05
RS60036B1 (sr) 2020-04-30
HRP20191249T1 (hr) 2019-10-18
PL3378850T3 (pl) 2020-07-27
KR20140126389A (ko) 2014-10-30
SI3312156T1 (sl) 2019-09-30
LT3378850T (lt) 2020-04-10
RU2632875C2 (ru) 2017-10-11
IL252459A0 (en) 2017-07-31
ES2735801T3 (es) 2019-12-20
EP2817288A2 (en) 2014-12-31
JP2015509496A (ja) 2015-03-30
MY168296A (en) 2018-10-23
MX350731B (es) 2017-09-15
MX344190B (es) 2016-12-08
IL252459B (en) 2020-03-31
DK3312156T3 (da) 2019-07-22
ES2773686T3 (es) 2020-07-14
AU2013203283B2 (en) 2015-11-26
RS59071B1 (sr) 2019-09-30
CR20140395A (es) 2014-11-17
KR101993248B1 (ko) 2019-06-26
SG11201405035XA (en) 2014-09-26
SMT202000107T1 (it) 2020-03-13
HRP20200245T1 (hr) 2020-05-15
IN2014DN06740A (es) 2015-05-22
TW201336815A (zh) 2013-09-16
SI3378850T1 (sl) 2020-07-31
HUE048412T2 (hu) 2020-07-28
EP3378850B8 (en) 2020-03-04
US20160031808A1 (en) 2016-02-04
ES2971710T3 (es) 2024-06-06
WO2013126360A2 (en) 2013-08-29
PH12014501865A1 (en) 2014-11-17
SMT201900397T1 (it) 2019-09-09
US9688623B2 (en) 2017-06-27
NZ628028A (en) 2016-03-31
RU2014138037A (ru) 2016-04-10
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
UA116773C2 (uk) 2018-05-10
PT3378850T (pt) 2020-03-06
AU2013203283A1 (en) 2013-09-05
DK3378850T3 (da) 2020-03-16
TR201910430T4 (tr) 2019-08-21
CA2864517A1 (en) 2013-08-29
EP3702347B1 (en) 2023-11-08
ES2675168T3 (es) 2018-07-09
EP3378850B1 (en) 2020-01-08
AR090100A1 (es) 2014-10-22
HUE044192T2 (hu) 2019-10-28
NI201400093A (es) 2016-11-30
CO7061071A2 (es) 2014-09-19
BR122021020046B1 (pt) 2022-05-31
CN112812044B (zh) 2023-05-30
PH12014501865B1 (en) 2014-11-17
US20170129852A1 (en) 2017-05-11
BR112014020444B1 (pt) 2021-12-07
IL273050A (en) 2020-04-30
PT3312156T (pt) 2019-07-19

Similar Documents

Publication Publication Date Title
AR117963A2 (es) Procesos para la preparación de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
MX390726B (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen tales compuestos.
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
SA518400493B1 (ar) مركبات كارفيلزوميب معالجة ببولي إيثيلين جليكول
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
AR090566A1 (es) Proceso para la produccion de inhibidores de crr
PH12016500963A1 (en) Novel dgat2 inhibitors
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
AR098522A1 (es) Compuesto de triazolo-piridina
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
AR105494A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
MX388612B (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
MX378591B (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico
MX2012013610A (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina.
WO2016089758A3 (en) Organo-1-oxa-4-azonium cyclohexane compounds
MX2021005343A (es) Proceso para la preparacion de isoxazolinas opticamente enriquecidas.
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2016001095A (es) Sales de dasatinib en forma cristalina.
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
EP3323506A4 (en) CATALYST OF A NANOCRYSTAL COMPOUNT FOR HYDROGEN STORAGE / SUPPLY, CATALYST MIXTURE OF A NANOCRYSTAL COMPLEX FOR HYDROGEN STORAGE / SUPPLY AND METHOD OF SUPPLEMENTING HYDROGEN
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
BR112016026310A8 (pt) processo para a reação de compostos químicos
BR112017003121A2 (pt) método para a síntese de um óxido de fosfina de hidrogênio heterocíclico
MX2018005146A (es) Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1.